Amorfix announces leading sensitivity for prion detection in spiked human blood samples
Amorfix Life Sciences Ltd. announced it had completed the analysis of the international reference blinded panels of human blood samples spiked with prions from variant Creutzfeldt-Jakob disease (vCJD) patients which were provided by the UK government.
"Our excellent results from the blinded panels match our previous internal tests using spiked blood samples. Based on data presented at industry conferences on 4 other laboratories and companies that have completed the blinded panels, we are confident that the company's EP-CJD(TM) assay is significantly more sensitive in detecting prions," said Dr. George Adams, Chief Executive Officer, Amorfix.
"Having superior sensitivity should give Amorfix a competitive advantage in the early detection of prions in blood from donors who are infected but do not yet show symptoms of the disease", said Dr. Neil Cashman, Chief Scientific Officer, Amorfix. "We look forward to testing blood samples from people who have unfortunately been infected with vCJD and preclinical samples from infected but asymptomatic animals to further validate the utility of the EP-CJD(TM) to secure the blood transfusion systems worldwide". Dr. Cashman will be presenting the blinded panel results at the Transmissible Spongiform Encephalopathies conference in Vienna, Austria, on June 28th.
The National vCJD Surveillance Unit (NCJDSU) and the British National Institute for Biological Standards and Controls (NIBSC) direct the international testing program and will publish an independent analysis of all these benchmarking results from those companies who participated. The NCJDSU has blood and tissue samples from approximately 150 people who have been diagnosed with vCJD and subsequently died. The company has sent a request to the British Department of Health, Tissue Management Group to access the final blinded panels containing blood samples from patients with variant CJD, patients with sporadic CJD, patients with other neurological conditions and "normal controls" from blood donors. These results will be used to apply for regulatory approval to market the test in Europe.
Organizations
Other news from the department research and development
These products might interest you

Whatman™ folded filter papers by Cytiva
Whatman folded filter papers
Convenient folded formats speed up your sample preparation

Systec H-Series by Systec
Safe, reproducible and validatable sterilization of liquids, solids and waste
Autoclaves with 65-1580 liters usable space, flexibly expandable for various applications

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
KDR Biotech markets DASGIP Parallel Bioreactor Systems in Korea

Virulence factor of the influenza A virus mapped in real-time

More sensitive MRI diagnostics thanks to innovative “elastic” contrast media
Emerging gene editing approach seeks broad spectrum crop disease resistance
Scientists sequence genome of the woodland strawberry, a model system for rosaceae plants - Research could provide model for other plants in the Rosaceae family, including almond, apple and peach
Paclitaxel
Genome comparison tools found to be susceptible to slip-ups
List_of_biomolecules
Category:Carotenoids

Acetylation: a Time-Keeper of glucocorticoid Sensitivity - Understanding the regulatory mechanism paves the way to enhance the effectiveness of anti-inflammatory therapies

When does it make sense to develop a new therapeutic agent? - Criteria that research must meet so that a substance that shows promise in the laboratory can actually be developed into a clinically effective drug
